Publication: Intravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous.
No Thumbnail Available
Date
2012-12-31T22:00:00Z
Authors
Authors
Ozsutcu, Mustafa
Gulkilik, Gokhan
Ayintap, Emre
Altinisik, Muhammed
Demirci, Goktug
Aras, Cengiz
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Abstract
To report 2 eyes of a patient which developed vitreomacular traction (VMT) 1 month after intravitreal bevacizumab (IVB) injection.
A 45-year-old female with bilateral diffuse diabetic macular edema (DME) received bilateral IVB.
Her initial visual acuity (VA) was 0.15 and 0.2 in OD and OS, respectively. Central foveal thickness (CFT) was 568 and 662 µm in OD and OS, respectively, without any sign of VMT. Both eyes responded well initially but developed VMT at 1 month. This time, intravitreal triamcinolone (IVTA) injection was performed. One month after IVTA injection, VMT was released and CFT decreased to 163 and 181 µm in OD and OS, respectively. Six months after IVTA injection, CFT was 163 and 153 µm, and VA was 0.7 and 0.9 in OD and OS, respectively.
In eyes with DME and attached posterior vitreous, VMT may develop after IVB injection and increase edema. IVTA injection might be an option to release VMT before considering vitrectomy.
A 45-year-old female with bilateral diffuse diabetic macular edema (DME) received bilateral IVB.
Her initial visual acuity (VA) was 0.15 and 0.2 in OD and OS, respectively. Central foveal thickness (CFT) was 568 and 662 µm in OD and OS, respectively, without any sign of VMT. Both eyes responded well initially but developed VMT at 1 month. This time, intravitreal triamcinolone (IVTA) injection was performed. One month after IVTA injection, VMT was released and CFT decreased to 163 and 181 µm in OD and OS, respectively. Six months after IVTA injection, CFT was 163 and 153 µm, and VA was 0.7 and 0.9 in OD and OS, respectively.
In eyes with DME and attached posterior vitreous, VMT may develop after IVB injection and increase edema. IVTA injection might be an option to release VMT before considering vitrectomy.
Description
Keywords
Bevacizumab, Diabetic macular edema, Posterior vitreous, Vitreomacular traction